welcome
Investor's Business Daily

Investor's Business Daily

Health

Health

BioNTech Surges On Summit's Coattails. Can They Rival Merck?

Investor's Business Daily
Summary
Nutrition label

83% Informative

Summit Therapeutics' drug, ivonescimab, works by blocking proteins called PD-1 and VEGF .

Leerink Partners analyst Daina Graybosch says the results have a highly promising readthrough for BioNTech stock.

Merck is also working on a drug that simultaneously blocks the proteins.

In the next study, Summit and Akeso plan to enroll patients with squamous and non-squamous forms of cancer.

VR Score

87

Informative language

90

Neutral language

42

Article tone

formal

Language

English

Language complexity

44

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

Affiliate links

no affiliate links

Small business owner?

Otherweb launches Autoblogger—a revolutionary way to bring more leads to any small business, using the power of AI.